MedTrace Logo

Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants

NCT04144816 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2019-10-30

No results posted yet for this study

Summary

The VRS (Respiratory Syncytial Virus) study group in Lyon is a working that aims to understand, predict and prevent the burden of disease caused by human respiratory syncytial virus (RSV) infection in infants. Incidence of RSV-associated hospitalization in the first year of life was estimated at 14.5 (95% CI 13.4-15.6) per 1000 births in a cohort study in Lyon, France. Related direct medical annual costs were estimated for this cohort at 364,269€, mostly attributed to children born during the RSV season (231,959€) and children born premature (108,673€). This study will combine existing hospital specimens and databases to determine the respective role of socio demographic factors, clinical risk factors, level of cord specific antibody at birth, and virus characteristic in the Respiratory Syncytial Virus (RSV) Hospitalization outcome in Infants.

Regarding the introduction of a new RSV vaccine and RSV-specific neutralizing antibodies, these data are of prime importance to guide future vaccine policies.

Conditions

  • Syncytial Virus Respiratory Infection
  • RSV Infection
  • Respiratory Syncytial Virus Infections
  • RSV Bronchiolitis

Interventions

OTHER

Not applicable (no intervention)

Not applicable (no intervention)

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
1 Day
Max Age
4 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2020-03-31
Completion
2020-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04144816 on ClinicalTrials.gov